FS-102 is under clinical development by F-star Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.
Establishment Labs wins FDA approval for Motiva breast implants
Dive Brief: Establishment Labs received Food and Drug Administration approval for its Motiva breast implants for primary and revision breast augmentation. Motiva is the first